Peak Asset Management LLC Purchases New Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Peak Asset Management LLC acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 5,192 shares of the medical equipment provider’s stock, valued at approximately $447,000.

Several other large investors have also modified their holdings of the business. DV Equities LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter worth approximately $25,000. Tacita Capital Inc purchased a new position in Zimmer Biomet during the 2nd quarter valued at $26,000. Monetary Solutions Ltd bought a new position in Zimmer Biomet in the 4th quarter valued at $30,000. Gen Wealth Partners Inc bought a new position in Zimmer Biomet in the 4th quarter valued at $31,000. Finally, Elevation Wealth Partners LLC increased its stake in Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 229 shares during the period. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on ZBH shares. Wells Fargo & Company lowered their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. UBS Group reissued a “buy” rating and issued a $120.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Citizens Jmp dropped their target price on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating on the stock in a research note on Wednesday, April 29th. Finally, Royal Bank Of Canada raised their target price on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $104.42.

Zimmer Biomet Stock Performance

ZBH stock opened at $100.89 on Tuesday. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29. The business has a 50-day moving average price of $92.90 and a 200 day moving average price of $91.14. The company has a market capitalization of $19.24 billion, a P/E ratio of 24.55, a PEG ratio of 2.75 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same quarter last year, the firm posted $2.07 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.28% of the stock is currently owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.